GATTO, MARIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.757
EU - Europa 1.142
AS - Asia 837
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
OC - Oceania 1
Totale 7.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.751
IT - Italia 482
CN - Cina 407
SG - Singapore 348
DE - Germania 118
NL - Olanda 114
FI - Finlandia 101
GB - Regno Unito 79
SE - Svezia 73
RU - Federazione Russa 48
FR - Francia 47
IE - Irlanda 41
IN - India 27
VN - Vietnam 26
HK - Hong Kong 15
GR - Grecia 9
EG - Egitto 7
CA - Canada 5
ES - Italia 5
UA - Ucraina 5
AT - Austria 4
CZ - Repubblica Ceca 3
RO - Romania 3
BD - Bangladesh 2
BR - Brasile 2
DZ - Algeria 2
EU - Europa 2
IR - Iran 2
JP - Giappone 2
MK - Macedonia 2
PL - Polonia 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
EE - Estonia 1
ID - Indonesia 1
IL - Israele 1
KG - Kirghizistan 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
TW - Taiwan 1
Totale 7.751
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Woodbridge 556
Chandler 548
Ashburn 455
Houston 443
Seattle 374
Ann Arbor 372
Cambridge 341
Wilmington 286
Singapore 281
Boardman 137
Santa Clara 132
Beijing 103
San Diego 101
Padova 100
Medford 80
Princeton 80
Des Moines 73
Helsinki 59
Nanjing 43
Dublin 41
Milan 27
Dong Ket 26
New York 20
Dearborn 19
Falls Church 18
London 14
Ogden 14
Rome 14
Hong Kong 12
Jinan 12
Guangzhou 11
Hefei 11
Pasian di Prato 10
Udine 10
Washington 10
Redwood City 9
Shenyang 9
Athens 8
Cagliari 8
Hebei 8
Nanchang 8
Naples 8
Shanghai 8
Bologna 7
Falkenstein 7
Florence 7
Los Angeles 7
Roxbury 7
Tianjin 7
Changsha 6
Lappeenranta 6
Las Vegas 6
Turin 6
Venice 6
Verona 6
Cairo 5
Jiaxing 5
Kunming 5
Nürnberg 5
Zhengzhou 5
Dallas 4
Frankfurt am Main 4
Genoa 4
Hangzhou 4
Ningbo 4
Rockville 4
Tappahannock 4
Vigonza 4
Acton 3
Brendola 3
Chicago 3
Haikou 3
Kharkiv 3
New Delhi 3
Orange 3
Phoenix 3
Pignone 3
Prescot 3
Stockholm 3
Vicenza 3
Windsor 3
Algiers 2
Amsterdam 2
Bangkok 2
Bergamo 2
Berlin 2
Bhopal 2
Bolzano 2
Bresso 2
Bussero 2
Caorle 2
Catanzaro 2
Cerea 2
Cesena 2
Chianciano Terme 2
Dongguan 2
Ergolding 2
Ferrara 2
Fremont 2
Totale 6.211
Salva come PNG Salva come JPEG
Nome #
ISEV2022 Abstract Book 222
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. 181
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 165
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. 157
Advances in the Diagnosis and Classification of Systemic Lupus Erythematosus 155
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis 142
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission 142
PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. 137
Overlap connective tissue disease syndromes. 130
A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab--comments on article by Fredericks et al. 129
17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. 127
Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: A literature review 124
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 124
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients 123
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 119
Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review 118
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis 117
The olfactory function is impaired in patients with idiopathic inflammatory myopathies. 116
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 116
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 116
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 115
Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity-a Comprehensive Review. 111
The clinical features, diagnosis and classification of dermatomyositis. 111
New therapeutic strategies in systemic lupus erythematosus management 111
Rheumatic and autoimmune thyroid disorders: a causal or casual relationship? 109
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes 108
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 102
Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. 102
Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. 99
Predictors of maternal and fetal complications in SLE patients: a prospective study. 99
Emerging and critical issues in the pathogenesis of lupus. 97
Optimizing outcome in SLE: treating-to-target and definition of treatment goals. 97
Premature coronary heart disease in SLE: can we prevent progression? 96
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 93
Belimumab: a step forward in the treatment of systemic lupus erythematosus 92
Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis 91
Lupus nephritis: clinical presentations and outcomes in the 21st century 90
Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study 88
Anti-MDA5 dermatomyositis: an update from bench to bedside 85
Remission in systemic lupus erythematosus: Testing different definitions in a large multicentre cohort 85
Novel Pathogenic Pathways and Therapeutic Implications in Lupus Nephritis: The Emerging Role of PTX3-Related Immunity 85
Human papillomavirus vaccine and systemic lupus erythematosus. 82
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 82
Vaccination of mice for research purpose: alum is as effective as and safer than complete Freund adjuvant. 81
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission 80
Autophagy in human health and disease. 79
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 79
Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis 76
Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study 75
Unresolved and critical issues in autoimmune rheumatic diseases 75
The body against self: autoinflammation and autoimmunity. 75
In-/off-label use of biologic therapy in systemic lupus erythematosus 73
Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. 71
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion 71
Role of galectin-3 in autoimmune and non-autoimmune nephropathies 70
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up 70
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 68
Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion 68
Pulmonary involvement in antisynthetase syndrome 68
Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. 67
Autoantibody testing in patients with myositis: clinical accuracy of a multi parametric line immunoassay 66
The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty? 64
Galectin-3 in autoimmunity and autoimmune diseases 63
Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: insights from renal ultrastructural findings.   61
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 60
Nonimmune mechanisms in idiopathic inflammatory myopathies 59
Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission 59
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis 58
Preclinical and early systemic lupus erythematosus 56
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 55
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts 55
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 52
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 51
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 51
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 48
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsets 47
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 47
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 45
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 44
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review 44
Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis 42
The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission 40
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 39
CHARACTERIZATION OF EXTRACELLULAR VESICLES SURFACE LYMPHOCYTES MARKERS AND MICRORNA CARGO IN PATIENTS AFFECTED WITH IDIOPATHIC INFLAMMATORY MYOPATHIES 34
Lymphocyte immunophenotyping in inflammatory myositis: a review 33
When to use belimumab in SLE 31
Cytoarchitectureal changes in hippocampal subregions of the NZB/W F1 mouse model of lupus 30
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 28
Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease 27
Evaluation of extracellular vesicles as potential biomarkers of myositis 27
Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate 25
The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study 22
Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus 19
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis 19
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 19
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab 19
Assessment of disease activity and damage in SLE: Are we there yet? 18
Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis 14
Evaluation of extracellular vesicles as potential myositis biomarkers 14
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 12
Totale 7.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.795
article - articoli 32.927
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020775 0 0 0 0 0 0 157 147 140 145 121 65
2020/20211.193 48 72 77 56 16 42 49 108 111 224 129 261
2021/20221.267 51 135 135 83 81 116 76 114 63 51 81 281
2022/20231.010 202 117 29 138 129 138 13 76 95 12 39 22
2023/2024765 27 74 88 67 63 104 60 47 46 24 79 86
2024/20251.142 13 185 121 145 324 108 246 0 0 0 0 0
Totale 7.897